{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:42:21Z","timestamp":1773297741529,"version":"3.50.1"},"reference-count":112,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Sexual Medicine"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1111\/j.1743-6109.2011.02590.x","type":"journal-article","created":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T07:12:53Z","timestamp":1326784373000},"page":"887-902","source":"Crossref","is-referenced-by-count":37,"title":["Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects"],"prefix":"10.1093","volume":"9","author":[{"given":"Giovanni","family":"Corona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Gacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Mancina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Forti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of PC and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/annonc\/mdq774","article-title":"European cancer mortality predictions for the year 2011","volume":"22","author":"Malvezzi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","article-title":"EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease","volume":"59","author":"Heidenreich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration\u2010resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/BF03347072","article-title":"Androgen regulation of prostate cancer: Where are we now?","volume":"34","author":"Corona","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen\u2010dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0040","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1210\/en.2002-0210","article-title":"Inhibition of spontaneous androgen\u2010induced prostate growth by non hypercalcemic calcitriol analog","volume":"144","author":"Crescioli","year":"2003","journal-title":"Endocrinology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0045","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1210\/endo.140.10.7039","article-title":"Androgen\u2010induced regrowth in the castrated rat ventral prostate: Role of 5alpha\u2010reductase","volume":"140","author":"Wright","year":"1999","journal-title":"Endocrinology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0050","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1743-6109.2009.01549.x","article-title":"The relationship of testosterone to prostate\u2010specific antigen in men with sexual dysfunction","volume":"7","author":"Corona","year":"2010","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/pcan.2010.4","article-title":"Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer","volume":"13","author":"Gacci","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0060","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/pros.21174","article-title":"Serum prostate\u2010specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu","volume":"70","author":"Takizawa","year":"2010","journal-title":"Prostate"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MED.0b013e32814db88c","article-title":"Androgen deprivation therapy for prostate cancer: New concepts and concerns","volume":"14","author":"Smith","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0070","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.juro.2009.01.047","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"181","author":"Saylor","year":"2009","journal-title":"J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006019","article-title":"Neo\u2010adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer","volume":"4","author":"Kumar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.10647","article-title":"Systematic review and meta\u2010analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma","volume":"95","author":"Samson","year":"2002","journal-title":"Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0085","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0090-4295(97)00279-3","article-title":"Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double\u2010blind, randomized, multicenter trial\u2014Casodex Combination Study Group","volume":"50","author":"Schellhammer","year":"1997","journal-title":"Urology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0095","article-title":"Early versus deferred androgen suppression in the treatment of advanced prostatic cancer","volume":"1","author":"Nair","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/01.ju.0000135742.13171.d2","article-title":"Early versus delayed endocrine treatment of pN1\u20103 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846\u2014A phase III study","volume":"172","author":"Schr\u00f6der","year":"2004","journal-title":"J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2008.09.008","volume":"55","author":"Schr\u00f6der","year":"2009","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short\u2010term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3816\/CGC.2002.n.018","article-title":"Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormonenaive prostate cancer: Results of a prospective randomized multicenter trial","volume":"1","author":"de Leval","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","article-title":"Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature","volume":"57","author":"Abrahamsson","year":"2010","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jsbmb.2006.09.032","article-title":"Prostate cancer risk in testosterone\u2010treated men","volume":"102","author":"Raynaud","year":"2006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1749-6632.2009.04115.x","article-title":"5alpha\u2010reductase isozymes and androgen actions in the prostate","volume":"1155","author":"Zhu","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00345-009-0493-y","article-title":"Current status of 5alpha\u2010reductase inhibitors in the management of lower urinary tract symptoms and BPH","volume":"28","author":"Gravas","year":"2010","journal-title":"World J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of PC","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0145","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0150","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MOU.0b013e3283381966","article-title":"Update on chemoprevention for prostate cancer","volume":"20","author":"Strope","year":"2010","journal-title":"Curr Opin Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0155","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJMe1001045","article-title":"Chemoprevention of prostate cancer","volume":"362","author":"Walsh","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/01.ju.0000136269.10161.32","article-title":"Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men","volume":"172","author":"Kaufman","year":"2004","journal-title":"J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0165","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/01.ju.0000143942.55896.64","article-title":"Testosterone replacement therapy after primary treatment for prostate cancer","volume":"173","author":"Agarwal","year":"2005","journal-title":"J Urol"},{"issue":"4","key":"10.1111\/j.1743-6109.2011.02590.x_bb0170","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0022-5347(08)61255-0","article-title":"Analysis of the PSA response after testosterone supplementation in patients who previously received management for their localized prostate cancer","volume":"179","author":"Davilla","year":"2008","journal-title":"J Urol"},{"issue":"4","key":"10.1111\/j.1743-6109.2011.02590.x_bb0175","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0022-5347(08)61189-1","article-title":"Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy","volume":"179","author":"Nabulsi","year":"2008","journal-title":"J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0180","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1743-6109.2009.01161.x","article-title":"Testosterone replacement therapy following radical prostatectomy","volume":"6","author":"Khera","year":"2009","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0185","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/j.1464-410X.2009.08980.x","article-title":"Testosterone replacement in prostate cancer survivors with hypogonadal symptoms","volume":"105","author":"Leibowitz","year":"2010","journal-title":"BJU Int"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1464-410X.2008.07882.x","article-title":"Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: Preliminary observations","volume":"103","author":"Morales","year":"2009","journal-title":"BJU Int"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0195","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cncr.22438","article-title":"Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy","volume":"109","author":"Sarosdy","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0200","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.juro.2010.11.084","article-title":"Testosterone therapy in men with untreated prostate cancer","volume":"185","author":"Morgentaler","year":"2011","journal-title":"J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2605.2008.00924.x","article-title":"Investigation, treatment, and monitoring of late\u2010onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations","volume":"32","author":"Wang","year":"2009","journal-title":"Int J Androl"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archsurg.1950.01250020438003","article-title":"Prostatic cancer: Further investigation of hormone relationships","volume":"61","author":"Brendler","year":"1950","journal-title":"Arch Surg"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0215","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.eururo.2009.03.073","article-title":"Phase 1 trial of high\u2010dose exogenous testosterone in patients with castration\u2010resistant metastatic prostate cancer","volume":"56","author":"Morris","year":"2009","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eururo.2009.02.022","article-title":"A randomized phase 1 study of testosterone replacement for patients with low\u2010risk castration\u2010resistant prostate cancer","volume":"56","author":"Szmulewitz","year":"2009","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0225","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.eururo.2009.10.021","article-title":"Re: Michael J. Morris, Daisy Huang, William K. Kelly et\u2003al. Phase 1 trial of high\u2010dose exogenous testosterone in patients with castration\u2010resistant metastatic prostate. Eur Urol 2009;56:237\u201344","volume":"57","author":"Drewa","year":"2010","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0230","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2007-2595","article-title":"Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis","volume":"93","author":"Shahani","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0235","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2164\/jandrol.108.005454","article-title":"Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth","volume":"29","author":"Basaria","year":"2008","journal-title":"J Androl"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0240","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2008.10.008","article-title":"Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefits and risks","volume":"55","author":"Isbarn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0245","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen\u2010deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0250","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1530\/EJE-11-0447","article-title":"Hypogonadism as a risk factor for cardiovascular mortality in men: A meta\u2010analytic study","volume":"165","author":"Corona","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0255","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long\u2010term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0260","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0265","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0270","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0275","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.10967","article-title":"Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0280","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/cncr.21381","article-title":"Changes in bone mineral density and body composition during initial and long\u2010term gonadotropin\u2010releasing hormone agonist treatment for prostate carcinoma","volume":"104","author":"Lee","year":"2005","journal-title":"Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0285","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"Dockery","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0290","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0295","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0300","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijir.3901471","article-title":"Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy","volume":"18","author":"Braga\u2010Basaria","year":"2006","journal-title":"Int J Impot Res"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0305","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0310","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0315","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D'Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0320","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0325","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92\u201002","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0330","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short\u2010term neoadjuvant androgen deprivation therapy and external\u2010beam radiotherapy for locally advanced prostate cancer: Long\u2010term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0335","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease\u2010induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0340","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85\u201031","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0345","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1464-410X.2010.09273.x","article-title":"Androgen\u2010suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke","volume":"106","author":"Hayes","year":"2010","journal-title":"BJU Int"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0355","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2010.03942.x","article-title":"Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy","volume":"74","author":"Hamilton","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0360","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5489\/cuaj.556","article-title":"Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non\u2010metastatic prostate cancer","volume":"5","author":"Mohamedali","year":"2011","journal-title":"Can Urol Assoc J"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0365","first-page":"29","article-title":"Sex steroids and sexual desire mechanism","volume":"26","author":"Rochira","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0370","first-page":"39","article-title":"Testosterone and sexual activity","volume":"28","author":"Vignozzi","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0375","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF01541244","article-title":"Castration for sex offenders: Treatment or punishment? A review and critique of recent European literature","volume":"8","author":"Heim","year":"1979","journal-title":"Arch Sex Behav"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0380","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jcem-57-3-557","article-title":"The nature of androgen action on male sexuality: A combined laboratory\u2010self\u2010report study on hypogonadal men","volume":"57","author":"Kwan","year":"1983","journal-title":"Clin Endocrinol Metab"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01542116","article-title":"Changes in erectile responsiveness during androgen replacement therapy","volume":"12","author":"Bancroft","year":"1983","journal-title":"Arch Sex Behav"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0390","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-5347(01)67675-4","article-title":"Visually stimulated erection in castrated men","volume":"153","author":"Greenstein","year":"1995","journal-title":"J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0395","series-title":"Hormones and behavior","first-page":"433","article-title":"Androgen replacement therapy in a wider context: Clinical and basic aspects","author":"Davidson","year":"1986"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0400","series-title":"Rome and China: Comparative perspective ancient world empire","first-page":"83","article-title":"Eunuchus, women and imperial courts","author":"Dettenhofer","year":"2009"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0405","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1210\/en.2003-1699","article-title":"Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa","volume":"145","author":"Morelli","year":"2004","journal-title":"Endocrinology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0410","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.eururo.2004.10.021","article-title":"Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum","volume":"47","author":"Zhang","year":"2005","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0415","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrurol.2009.235","article-title":"The role of testosterone in erectile dysfunction","volume":"7","author":"Corona","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1111\/j.1743-6109.2011.02590.x_bb0420","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2605.2005.00594.x","article-title":"The impotent couple: Low desire","volume":"28","author":"Corona","year":"2005","journal-title":"Int J Androl"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0425","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2265.2005.02350.x","article-title":"Effects of testosterone on sexual function in men: Results of a meta\u2010analysis","volume":"63","author":"Isidori","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0430","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-5347(17)64668-8","article-title":"Sexual function in aging males after orchidectomy and estrogen therapy","volume":"89","author":"Ellis","year":"1963","journal-title":"J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0435","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01542054","article-title":"Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration","volume":"17","author":"Rousseau","year":"1988","journal-title":"Arch Sex Behav"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0440","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1442-2042.1999.06128.x","article-title":"Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone\u2010releasing hormone agonist therapy","volume":"6","author":"Marumo","year":"1999","journal-title":"Int J Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0445","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2001.19.17.3750","article-title":"Quality\u2010of\u2010life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study","volume":"19","author":"Potosky","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0450","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cncr.10656","article-title":"The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma","volume":"95","author":"Fowler","year":"2002","journal-title":"Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0455","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1743-6109.2010.02164.x","article-title":"Randomized, double\u2010blinded, placebo\u2010controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short\u2010term androgen deprivation therapy: Results of RTOG 0215","volume":"8","author":"Watkins Bruner","year":"2011","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0460","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1111\/j.1743-6109.2010.01902.x","article-title":"Androgen deprivation therapy for prostate cancer: Recommendations to improve patient and partner quality of life","volume":"7","author":"Elliott","year":"2010","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0465","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0090-4295(99)80092-2","article-title":"Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report","volume":"45","author":"Goldenberg","year":"1995","journal-title":"Urology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0470","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0090-4295(96)00381-0","article-title":"Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study","volume":"48","author":"Higano","year":"1996","journal-title":"Urology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0475","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3816\/CGC.2008.n.008","article-title":"Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate\u2010specific antigen relapse after radiation therapy for locally advanced prostate cancer","volume":"6","author":"Bruchovsky","year":"2008","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1111\/j.1743-6109.2011.02590.x_bb0480","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1743-6109.2008.01159.x","article-title":"Androgens and erectile function: A case for early androgen use in postprostatectomy hypogonadal men","volume":"6","author":"Khera","year":"2009","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0485","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1743-6109.2008.01208.x","article-title":"Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism","volume":"6","author":"Vignozzi","year":"2009","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0490","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ejca.2006.01.029","article-title":"Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer","volume":"42","author":"Spry","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0495","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/j.1743-6109.2009.01352.x","article-title":"Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism","volume":"6","author":"Corona","year":"2009","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0500","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jnci\/djm023","article-title":"Longitudinal analysis of sexual function reported by men in the prostate cancer prevention trial","volume":"99","author":"Moinpour","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0505","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2164\/jandrol.108.005025","article-title":"The effect of 5a\u2010reductase inhibitors on erectile function","volume":"29","author":"Canguven","year":"2008","journal-title":"J Androl"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0510","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1111\/j.1743-6109.2008.01001.x","article-title":"5a reductase inhibitors and erectile dysfunction: The connection","volume":"5","author":"Erdemir","year":"2008","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0515","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","article-title":"The effect of finasteride in men with benign prostatic hyperplasia: The finasteride study group","volume":"327","author":"Gormley","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0520","first-page":"1251","article-title":"Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2\u2010year randomized controlled trial (the PROSPECT study). Proscar safety plus efficacy Canadian two year study","volume":"155","author":"Nickel","year":"1996","journal-title":"CMAJ"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0525","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000019706","article-title":"Sustained\u2010release alfuzosin, finasteride and combination of both in the treatment of benign prostatic hyperplasia. European ALFIN study group","volume":"34","author":"Debruyne","year":"1998","journal-title":"Eur Urol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0530","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0090-4295(94)90068-X","article-title":"Three\u2010year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia","volume":"43","author":"Stoner","year":"1994","journal-title":"Urology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0535","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0090-4295(02)02401-9","article-title":"Incidence and severity of sexual adverse experiences in finasteride and placebo treated men with benign prostatic hyperplasia","volume":"61","author":"Wessels","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0540","first-page":"1934","article-title":"Inhibition of steroid 5 alpha\u2010reductase with finasteride: Sleep\u2010related erections, potency, and libido in healthy men","volume":"80","author":"Cunningham","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0545","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.140.7.857","article-title":"Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia","volume":"140","author":"Tosti","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0550","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1468-3083.2001.00315.x","article-title":"Evaluation of sexual function in subjects taking finasteride for androgenetic alopecia","volume":"15","author":"Tosti","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0555","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","article-title":"Finasteride 5\u2003mg and sexual side effects: How many of these are related to a nocebo phenomenon?","volume":"4","author":"Mondaini","year":"2007","journal-title":"J Sex Med"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0560","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.urology.2004.01.001","article-title":"Efficacy and safety of dutasteride in the four\u2010year treatment of men with benign prostatic hyperplasia","volume":"63","author":"Roehrborn","year":"2004","journal-title":"Urology"},{"key":"10.1111\/j.1743-6109.2011.02590.x_bb0565","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0302-2838(03)00198-2","article-title":"Safety and tolerability of the dual 5 alpha\u2010reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia","volume":"44","author":"Andriole","year":"2003","journal-title":"Eur Urol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515338923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515338923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:42:02Z","timestamp":1672774922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1743609515338923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1743609515338923"],"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02590.x","relation":{},"ISSN":["1743-6095"],"issn-type":[{"value":"1743-6095","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}